KR860001944B1 - 카보스티릴 화합물의 제조방법 - Google Patents

카보스티릴 화합물의 제조방법 Download PDF

Info

Publication number
KR860001944B1
KR860001944B1 KR1019810004240A KR810004240A KR860001944B1 KR 860001944 B1 KR860001944 B1 KR 860001944B1 KR 1019810004240 A KR1019810004240 A KR 1019810004240A KR 810004240 A KR810004240 A KR 810004240A KR 860001944 B1 KR860001944 B1 KR 860001944B1
Authority
KR
South Korea
Prior art keywords
group
groups
compound
piperazinyl
carbostyryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019810004240A
Other languages
English (en)
Korean (ko)
Other versions
KR830007607A (ko
Inventor
미찌아끼 도미나가
양영웅
히데노리 오가와
가즈유끼 나까가와
Original Assignee
오쯔까 세이야꾸 가부시끼 가이샤
오쯔까 아끼히꼬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오쯔까 세이야꾸 가부시끼 가이샤, 오쯔까 아끼히꼬 filed Critical 오쯔까 세이야꾸 가부시끼 가이샤
Publication of KR830007607A publication Critical patent/KR830007607A/ko
Priority to KR1019860007986A priority Critical patent/KR860001959B1/ko
Priority to KR1019860007987A priority patent/KR860001960B1/ko
Priority to KR1019860007984A priority patent/KR860001945B1/ko
Priority to KR1019860007985A priority patent/KR860001958B1/ko
Application granted granted Critical
Publication of KR860001944B1 publication Critical patent/KR860001944B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1019810004240A 1980-10-31 1981-10-31 카보스티릴 화합물의 제조방법 Expired KR860001944B1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019860007986A KR860001959B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007987A KR860001960B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007984A KR860001945B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007985A KR860001958B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP55154071A JPS5777676A (en) 1980-10-31 1980-10-31 Carbostyril derivative
JP154071/80 1980-10-31

Related Child Applications (4)

Application Number Title Priority Date Filing Date
KR1019860007987A Division KR860001960B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007985A Division KR860001958B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007986A Division KR860001959B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법
KR1019860007984A Division KR860001945B1 (ko) 1980-10-31 1986-09-24 카보스티릴 화합물의 제조방법

Publications (2)

Publication Number Publication Date
KR830007607A KR830007607A (ko) 1983-11-04
KR860001944B1 true KR860001944B1 (ko) 1986-11-01

Family

ID=15576252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810004240A Expired KR860001944B1 (ko) 1980-10-31 1981-10-31 카보스티릴 화합물의 제조방법

Country Status (24)

Country Link
US (1) US4415572A (https=)
JP (1) JPS5777676A (https=)
KR (1) KR860001944B1 (https=)
AR (2) AR242563A1 (https=)
AT (1) AT381701B (https=)
AU (1) AU524419B2 (https=)
BE (1) BE890942A (https=)
CA (1) CA1209575A (https=)
CH (2) CH656616A5 (https=)
DE (2) DE3153260C2 (https=)
DK (1) DK155665C (https=)
ES (3) ES8306743A1 (https=)
FI (1) FI77450C (https=)
FR (2) FR2493320B1 (https=)
GB (1) GB2086896B (https=)
IT (2) IT1210585B (https=)
MX (1) MX8481A (https=)
NL (2) NL194205C (https=)
NO (1) NO158099C (https=)
PH (1) PH17962A (https=)
PT (1) PT73910B (https=)
SE (2) SE448877B (https=)
SU (1) SU1426452A3 (https=)
ZA (1) ZA817515B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5883677A (ja) * 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS5929667A (ja) * 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
CH655110A5 (de) * 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AU577802B2 (en) * 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
US4774246A (en) * 1984-01-26 1988-09-27 Abbott Laboratories Quinoline antibacterial compounds
NZ212209A (en) * 1984-05-29 1988-08-30 Pfizer Quinolone derivatives and pharmaceutical compositions
JPS60256133A (ja) * 1984-06-01 1985-12-17 Fuji Photo Film Co Ltd 放射線画像情報記録読取装置
DE3582371D1 (de) * 1984-07-06 1991-05-08 Otsuka Pharma Co Ltd Oxindolverbindungen, diese enthaltende zusammensetzungen sowie verfahren zur herstellung derselben.
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
JPH07100696B2 (ja) * 1984-12-18 1995-11-01 大塚製薬株式会社 カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3586794T2 (de) * 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
EP0185429A1 (en) * 1984-12-21 1986-06-25 Duphar International Research B.V New bicyclic heteroaryl piperazines
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
DE3524067A1 (de) * 1985-07-05 1987-01-08 Boehringer Mannheim Gmbh Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
US4666913A (en) * 1985-11-22 1987-05-19 William H. Rorer, Inc. Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses
GB8529362D0 (en) * 1985-11-28 1986-01-02 Pfizer Ltd Quinolone cardiac stimulants
JPH0625123B2 (ja) * 1985-12-12 1994-04-06 大塚製薬株式会社 カルボスチリル誘導体−シクロデキストリン包接化合物
US4689325A (en) * 1985-12-23 1987-08-25 Abbott Laboratories Isoxazolo-pyrido-phenoxazine and isothiazolo-pyrido-phenoxazine derivatives
US4687770A (en) * 1985-12-23 1987-08-18 Abbott Laboratories Isoxazolo-pyrido-benzoxazine and isothiazolo-pyrido-benzoxazine derivatives
DK111387A (da) * 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
GB8630702D0 (en) * 1986-12-23 1987-02-04 Wellcome Found Quinoline compound
US5166160A (en) * 1986-12-23 1992-11-24 Burroughs Wellcome Co. Quinoline compound
JPS63225357A (ja) * 1987-03-12 1988-09-20 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
CA2090876A1 (en) * 1991-07-03 1993-01-04 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
US5543412A (en) * 1991-07-03 1996-08-06 Otsuka Pharmaceutical Co., Ltd. Hepatitis treatment with carbostyril compounds
WO1993011769A1 (fr) * 1991-12-10 1993-06-24 Otsuka Pharmaceutical Co., Ltd Agent anticancereux
JP2686887B2 (ja) * 1992-08-11 1997-12-08 キッセイ薬品工業株式会社 ピペリジノ−３，４−ジヒドロカルボスチリル誘導体
AU666577B2 (en) * 1992-08-19 1996-02-15 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
JP2826790B2 (ja) * 1992-12-26 1998-11-18 キッセイ薬品工業株式会社 ３，４−ジヒドロカルボスチリル誘導体
WO1994020107A1 (fr) * 1993-03-02 1994-09-15 Otsuka Pharmaceutical Co., Ltd. Inhibiteur de rejet pour transplantations et inhibiteur de production d'interleukine 1
JPH0733664A (ja) * 1993-07-26 1995-02-03 Otsuka Pharmaceut Co Ltd 平滑筋細胞増殖抑制剤
GB9326373D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Chemical compounds
GB9326232D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Chemical compounds
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
DE69736704T2 (de) 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
GB2312843A (en) * 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
US5684007A (en) * 1996-09-05 1997-11-04 Otsuka Pharmaceutical Co., Ltd. Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis
TR200200507T2 (tr) * 1999-08-27 2002-10-21 Ligand Pharmaceuticals Inc Androjen reseptörü modülatör bileşikleri ve metotları
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
AU7586600A (en) 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
WO2006097459A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
AU2006296004B2 (en) 2005-09-27 2011-11-17 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278385B (de) * 1965-03-30 1968-09-26 Bayer Ag Aufhellungsmittel
GB1299172A (en) * 1968-10-15 1972-12-06 Lilly Industries Ltd Heterocyclic anti-inflammatory agents
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
JPS54130589A (en) * 1978-03-31 1979-10-09 Yoshitomi Pharmaceut Ind Ltd Pyridazine derivative and its preparation
JPS54135785A (en) * 1978-04-12 1979-10-22 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative and its preparation
JPS54138585A (en) * 1978-04-18 1979-10-27 Yoshitomi Pharmaceut Ind Ltd Pyridazine derivative and its preparation
JPS54141785A (en) * 1978-04-26 1979-11-05 Yoshitomi Pharmaceut Ind Ltd Preparation of carboxylic acid derivative
JPS6017072B2 (ja) * 1978-09-05 1985-04-30 三菱電機株式会社 赤熱金属検出器
JPS5549319A (en) * 1978-10-06 1980-04-09 Yoshitomi Pharmaceut Ind Ltd Remedy for suppression of blood platelet-agglutination
JPS5553283A (en) * 1978-10-12 1980-04-18 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative
JPS5576872A (en) * 1978-12-06 1980-06-10 Yoshitomi Pharmaceut Ind Ltd Imidazolidinone derivative
JPS5583781A (en) * 1978-12-19 1980-06-24 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative

Also Published As

Publication number Publication date
AR242375A1 (es) 1993-03-31
NL8104923A (nl) 1982-05-17
ES507198A0 (es) 1983-06-16
CH656616A5 (de) 1986-07-15
SE8406209D0 (sv) 1984-12-06
ES520638A0 (es) 1984-04-16
AU524419B2 (en) 1982-09-16
BE890942A (fr) 1982-02-15
NO158099C (no) 1988-07-13
JPS5777676A (en) 1982-05-15
ES8403886A1 (es) 1984-04-16
NO813678L (no) 1982-05-03
GB2086896A (en) 1982-05-19
ES520637A0 (es) 1984-04-16
FR2493320B1 (fr) 1985-08-23
CA1209575A (en) 1986-08-12
SE448877B (sv) 1987-03-23
FR2552760B1 (fr) 1988-08-05
AR242563A1 (es) 1993-04-30
IT8149588A0 (it) 1981-10-29
KR830007607A (ko) 1983-11-04
IT8547867A0 (it) 1985-03-26
JPH0143747B2 (https=) 1989-09-22
SE8406209L (sv) 1984-12-06
NL194205B (nl) 2001-05-01
FI77450C (fi) 1989-03-10
FR2493320A1 (fr) 1982-05-07
GB2086896B (en) 1984-10-10
ES8403885A1 (es) 1984-04-16
PH17962A (en) 1985-02-20
DK155665C (da) 1989-09-04
ZA817515B (en) 1982-10-27
PT73910B (en) 1983-04-18
SE466655B (sv) 1992-03-16
DK155665B (da) 1989-05-01
NL194205C (nl) 2001-09-04
DE3153260C2 (https=) 1989-05-24
AT381701B (de) 1986-11-25
DE3153260A1 (https=) 1985-05-15
IT1210585B (it) 1989-09-14
NO158099B (no) 1988-04-05
ES8306743A1 (es) 1983-06-16
IT1226479B (it) 1991-01-16
DK480381A (da) 1982-05-01
CH650782A5 (de) 1985-08-15
FI813408L (fi) 1982-05-01
US4415572A (en) 1983-11-15
AU7699681A (en) 1982-05-06
MX8481A (es) 1994-02-28
ATA460281A (de) 1986-04-15
FR2552760A1 (fr) 1985-04-05
DE3142982C2 (de) 1985-12-19
PT73910A (en) 1981-11-01
NL8403096A (nl) 1985-02-01
DE3142982A1 (de) 1982-06-24
SU1426452A3 (ru) 1988-09-23
SE8106430L (sv) 1982-05-01
FI77450B (fi) 1988-11-30

Similar Documents

Publication Publication Date Title
KR860001944B1 (ko) 카보스티릴 화합물의 제조방법
KR860001337B1 (ko) 카르보스티릴 유도체의 제법
US4760064A (en) Carbostyril compounds, compositions containing same and processes for preparing same
JPH0314308B2 (https=)
JPH0314023B2 (https=)
JPH0471914B2 (https=)
US4737501A (en) Substituted piperazinyl oxindol compounds and cardiotonic compositions containing the same
JPH0141128B2 (https=)
KR860001959B1 (ko) 카보스티릴 화합물의 제조방법
KR860001958B1 (ko) 카보스티릴 화합물의 제조방법
KR860001960B1 (ko) 카보스티릴 화합물의 제조방법
KR860001945B1 (ko) 카보스티릴 화합물의 제조방법
JPS649313B2 (https=)
JPH0216299B2 (https=)
JPS60130573A (ja) ベンゾチアゾ−ル誘導体
JPS63225357A (ja) カルボスチリル誘導体
JPS61267556A (ja) カルボスチリル誘導体
JPH0240646B2 (https=)
JPH08143566A (ja) キナゾリン誘導体及びそれを含有する医薬組成物
JPH0544462B2 (https=)
DK159436B (da) Substituerede piperazino-substituerede phenylcarboxylsyreforbindelser
JPH0249769A (ja) カルボスチリル誘導体
JPS647968B2 (https=)
JPS643194B2 (https=)
JPH0310620B2 (https=)

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19811031

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19830725

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19811031

Comment text: Patent Application

PG1501 Laying open of application
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19860419

Patent event code: PE09021S01D

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19860724

Patent event code: PE09021S01D

PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19861002

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19870120

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19870217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19870217

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19891005

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19901010

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19911022

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19921015

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19931015

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19941021

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19951025

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 19961030

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 19971029

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 19981020

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 19991019

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20001025

Start annual number: 15

End annual number: 15

PC1801 Expiration of term